CCI Acknowledges Union Of Nine Pharma With Sequent Scientific
The merger will streamline operations and strengthen the company’s position in animal and human healthcare;
By: : Ajay Singh
Update: 2025-01-21 18:00 GMT
CCI Acknowledges Union Of Nine Pharma With Sequent Scientific
The merger will streamline operations and strengthen the company’s position in animal and human healthcare
The Competition Commission of India (CCI) has approved the amalgamation of nine entities with pharmaceutical firm Sequent Scientific Ltd (SSL).
The competition regulator stated, "The proposed combination involves a series of inter-connected steps carried out for the amalgamation of Sequent Research Ltd, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity.”
SSL offers active pharmaceutical ingredients (APIs), finished dosage formulations, and analytical services for the animal health sector.
Sequent Research Ltd (SRL) is a wholly-owned subsidiary of SSL and a contract research organization.
Viyash, a pharmaceutical company, through its subsidiaries, engages in the development, manufacture and sale of APIs and intermediates for human healthcare in India.
Symed Labs, Appcure Labs, Vindhya Pharma (India) and Vandana Life Sciences are wholly-owned subsidiaries of Viyash while SV Labs is a wholly-owned step-down subsidiary of Viyash.